Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

舒尼替尼 医学 肾细胞癌 内科学 危险系数 中止 胃肠病学 临床终点 不利影响 对数秩检验 替西罗莫司 无进展生存期 肿瘤科 泌尿科 比例危险模型 随机对照试验 置信区间 总体生存率 细胞凋亡 化学 mTOR抑制剂的发现与发展 蛋白激酶B 生物化学
作者
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Stéphane Oudard,Sylvie Négrier,Cezary Szczylik,Роберто Пили,Georg A. Bjarnason,Xavier García del Muro,Jeffrey A. Sosman,E Solska,George Wilding,John A. Thompson,Sindy T. Kim,Isan Chen,Xin Huang,Robert A. Figlin
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (11): 1965-1971 被引量:159
标识
DOI:10.1200/jco.22.02623
摘要

Purpose A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported. Patients and Methods Seven hundred fifty treatment-naïve patients with metastatic clear cell RCC were randomly assigned to sunitinib 50 mg orally once daily on a 4 weeks on, 2 weeks off dosing schedule or to IFN-α 9 MU subcutaneously thrice weekly. Overall survival was compared by two-sided log-rank and Wilcoxon tests. Progression-free survival, response, and safety end points were assessed with updated follow-up. Results Median overall survival was greater in the sunitinib group than in the IFN-α group (26.4 v 21.8 months, respectively; hazard ratio [HR] = 0.821; 95% CI, 0.673 to 1.001; P = .051) per the primary analysis of unstratified log-rank test ( P = .013 per unstratified Wilcoxon test). By stratified log-rank test, the HR was 0.818 (95% CI, 0.669 to 0.999; P = .049). Within the IFN-α group, 33% of patients received sunitinib, and 32% received other vascular endothelial growth factor–signaling inhibitors after discontinuation from the trial. Median progression-free survival was 11 months for sunitinib compared with 5 months for IFN-α ( P < .001). Objective response rate was 47% for sunitinib compared with 12% for IFN-α ( P < .001). The most commonly reported sunitinib-related grade 3 adverse events included hypertension (12%), fatigue (11%), diarrhea (9%), and hand-foot syndrome (9%). Conclusion Sunitinib demonstrates longer overall survival compared with IFN-α plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC. The overall survival highlights an improved prognosis in patients with RCC in the era of targeted therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Grace159完成签到 ,获得积分10
刚刚
咖啡博士发布了新的文献求助10
2秒前
彦祖i学术完成签到,获得积分10
4秒前
zq完成签到,获得积分20
5秒前
HY完成签到,获得积分10
6秒前
不再挨训完成签到 ,获得积分10
7秒前
学术乞丐完成签到,获得积分20
9秒前
咖啡博士完成签到,获得积分10
10秒前
韭黄发布了新的文献求助10
11秒前
Singularity完成签到,获得积分0
13秒前
JamesPei应助zq采纳,获得10
14秒前
所所应助韭黄采纳,获得10
18秒前
江霭完成签到,获得积分10
21秒前
鲤鱼青槐完成签到,获得积分10
30秒前
量子星尘发布了新的文献求助10
31秒前
34秒前
缥缈的冰旋完成签到,获得积分10
34秒前
40秒前
41秒前
ailemonmint完成签到 ,获得积分10
41秒前
42秒前
玉ER完成签到,获得积分10
43秒前
44秒前
四十四次日落完成签到 ,获得积分10
44秒前
科研通AI2S应助羊二呆采纳,获得10
44秒前
英吉利25发布了新的文献求助10
46秒前
47秒前
水晶茶杯发布了新的文献求助10
48秒前
欢欢完成签到,获得积分10
49秒前
茯苓完成签到 ,获得积分10
51秒前
小鱼发布了新的文献求助10
52秒前
香香丿完成签到 ,获得积分10
52秒前
53秒前
万能图书馆应助zz123采纳,获得10
53秒前
杜康完成签到,获得积分10
53秒前
Cheung2121发布了新的文献求助10
53秒前
医学小王完成签到 ,获得积分10
54秒前
56秒前
刘涵完成签到 ,获得积分10
57秒前
帅气的沧海完成签到 ,获得积分10
58秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022